<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065259</url>
  </required_header>
  <id_info>
    <org_study_id>CON-I-07-CN-029-B</org_study_id>
    <nct_id>NCT01065259</nct_id>
  </id_info>
  <brief_title>Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children</brief_title>
  <official_title>Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the effect of Concerta (Osmotic Release Oral System&#xD;
      Extended Release Methylphenidate HCL, OROS MPH) and Strattera (Atomoxetine) on the laboratory&#xD;
      and ecological executive function in children with attention deficit hyperactivity disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample will include 134 ADHD children and adolescence, randomized assigned to Concerta&#xD;
      and strattera treatment group, with 67 cases in each. It will also include 67 sex and age&#xD;
      matched normal control. The drug will be titrated to optimal dose. The executive function&#xD;
      including inhibition, working memory, set shifting and plan will be compared among two&#xD;
      medication group and the control group, using laboratory executive function test and Behavior&#xD;
      Rating Inventory of Executive Function (BRIEF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Executive function test</measure>
    <time_frame>seven to ten weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD Rating Scale-IV</measure>
    <time_frame>seven to ten weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>OROS MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group treated by OROS MPH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the group treated by atomoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the normal control with no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS MPH</intervention_name>
    <description>The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks</description>
    <arm_group_label>OROS MPH</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.</description>
    <arm_group_label>atomoxetine</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 6 to 16 years old. Body weight between 20 to 60 kg&#xD;
&#xD;
          -  Meet ADHD criteria in tne Diagnostic and Statistic Manual of Mental Disorders, fourth&#xD;
             edition (DSM-IV) through questionaire and interview&#xD;
&#xD;
          -  Intelligence quotient (IQ) &gt;= 70&#xD;
&#xD;
          -  Currently unmedicated or effectively medicated with immediately released&#xD;
             methylphenidate (The maximum dosage no more than 60mg/d)&#xD;
&#xD;
          -  The patient and the parent express their will to comply with the follow up including&#xD;
             the clinical interview and all the test&#xD;
&#xD;
          -  The parent or the guardian sign the written consent&#xD;
&#xD;
          -  Can swallow the capsule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have administered immediate release methylphenidate, OROS MPH or atomoxetine, but ADHD&#xD;
             symptoms not improved.&#xD;
&#xD;
          -  Bipolar I or II disorder, psychosis, or pervasive developmental disorder.&#xD;
&#xD;
          -  Meet the DSM-IV anxiety disorder.&#xD;
&#xD;
          -  Any seizure disorder (except for febrile convulsion) or electroencephalogram (EEG)&#xD;
             abnormal associated with epilepsy, or currently taking anti-convulsion drugs.&#xD;
&#xD;
          -  Depression disorder, tend to commit suicide, or comorbid depression symptoms which&#xD;
             need immediate treatment.&#xD;
&#xD;
          -  Tics disorder, or Tourette's syndrom（DSM-IV 307.23）, or family history of tics&#xD;
             disorder.&#xD;
&#xD;
          -  Narrow-angle glaucoma&#xD;
&#xD;
          -  cardiovascular diseases, or any diseases may be deteriorated when the pulse or the&#xD;
             blood pressure increased, including hypertension or those taking anti-hypertension&#xD;
             drugs.&#xD;
&#xD;
          -  Diseases significantly enhance the sympathetic nervous system activity, or taking&#xD;
             sympathomimetic drug every day.&#xD;
&#xD;
          -  Allergic to methylphenidate or atomoxetine, or serious allergic reaction to more than&#xD;
             one drugs or adverse event to multiple drugs before.&#xD;
&#xD;
          -  Serious gastrointestinal stenosis&#xD;
&#xD;
          -  History of alcohol, drug or other substance abuse&#xD;
&#xD;
          -  Those using unprescribed potential abuse drugs in screening.&#xD;
&#xD;
          -  In the process of the trial, the patient need to take other psychotropic drug other&#xD;
             than the experimental drugs, including health food with central nervous system (CNS)&#xD;
             activity (e.g. melatonin).&#xD;
&#xD;
          -  Might begin any structure psychological therapy addressed for ADHD in the process of&#xD;
             the trial&#xD;
&#xD;
          -  Have used other psychotropic drugs in the past 30 days, including monoamine oxidase&#xD;
             inhibitor.&#xD;
&#xD;
          -  Are participating other clinical trial.&#xD;
&#xD;
          -  Have difficulty in following up in 8 weeks.&#xD;
&#xD;
          -  Relatives of the investigator.&#xD;
&#xD;
          -  Employee of Xi-an Jensen or Eli lilly company.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yufeng Wang, M.D. PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yufeng Wang</name_title>
    <organization>Peking University the Sixth Hospital</organization>
  </responsible_party>
  <keyword>attention deficit hyperactivity disorder</keyword>
  <keyword>executive function</keyword>
  <keyword>OROS MPH</keyword>
  <keyword>atomoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

